Bob Nelsen woos John Maraganore to his first VC post af­ter re­tir­ing from Al­ny­lam

Af­ter al­most two decades of pri­mar­i­ly be­ing known as Al­ny­lam’s CEO, John Maraganore is get­ting a new, promi­nent ti­tle.

Maraganore is among a slate of new ven­ture part­ners at ARCH Ven­ture, join­ing along­side ex-FDA of­fi­cial Lu­ciana Bo­rio, Jake Bauer (pre­vi­ous­ly at MyoKar­dia), Ax­el Bou­chon (for­mer head of Leaps by Bay­er) and Sabah Oney (of Alec­tor fame).

The move was hard­ly sur­pris­ing. Maraganore has made it clear that his re­tire­ment, which is sched­uled for the end of the year, sig­naled a shift in­to a new phase of his ca­reer where, in­stead of hands-on par­ent­ing, he want­ed to be like a “grand­fa­ther” to the next gen­er­a­tion of biotech star­tups, im­part­ing hard-earned wis­dom about the treach­er­ous jour­ney from the lab to mar­ket — one he per­son­al­ly shep­herd­ed Al­ny­lam and its RNAi sci­ence through.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER